Skip to content

Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial

Post Discharge After Surgery Virtual Care with Remote Automated Monitoring Technology-2 (PVC-RAM-2) Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04876950
Acronym
PVC-RAM-2
Enrollment
2000
Registered
2021-05-07
Start date
2024-10-04
Completion date
2026-03-31
Last updated
2024-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Complication, Surgery

Keywords

Virtual care, Remote monitoring, Acute hospital care

Brief summary

The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology-2 (PVC-RAM-2) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on acute-hospital care during the 45-day follow up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. Secondary outcomes at 45 days after randomization include 1) days in hospital; 2) index length of hospital stay; 3) hospital re-admission; 4) emergency department visit; 5) medication error detection; 6) medication error correction; and 7) surgical site infection. Additional secondary outcomes are pain of any severity, and moderate-to-severe pain assessed at 15 and 45 days. We will also assess optimal management of long-term health by evaluating among self-reported current smokers and those with atherosclerotic disease, whether patients are taking classes of efficacious medications at 45 days post randomization.

Interventions

COMBINATION_PRODUCTVirtual care with remote automated monitoring

Use of Cloud Diagnostics connected health kit for at home monitoring with virtual clinical from nursing and perioperative physician team.

Sponsors

Population Health Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. are ≥40 years of age; 2. will undergo or have undergone semi-urgent, urgent, or emergency surgery requiring expected hospital stay of ≥2 days; and 3. provide informed consent to participate.

Exclusion criteria

1. planned transfer to a rehabilitation or convalescent facility, or repatriation from trial hospital site to local community hospital following surgery; 2. are unable to communicate with research staff, complete study surveys, or undertake an interview using a tablet computer due to a language barrier or a cognitive, visual, or hearing impairment; or 3. reside in an area without cellular network coverage.

Design outcomes

Primary

MeasureTime frameDescription
Acute-hospital care45 days post randomizationComposite outcome of hospital re-admission and emergency department visit, which includes urgent-care centre visit.

Secondary

MeasureTime frameDescription
Hospital readmission45 days post randomizationPatient admission to an acute-care hospital.
Emergency department visit45 days post randomizationPatient visit to an emergency department.
Medication error detection45 days post randomizationMedication errors include mistakes in medication prescribing, transcribing, dispensing, administering, or monitoring due to preventable events or actions taken by a patient, caregiver, or healthcare worker. Medication errors include: drug omission (i.e., patient did not take a drug they were supposed to take), drug commission (i.e., patient taking a drug they were not supposed to take), duration error, dosing error, frequency error, route error, and timing error. We will record all drug errors identified and also report whether they resulted in harm.
Medication error correction45 days post randomizationAny medication error that is corrected.
Surgical site infection45 days post randomizationSurgical site infection is an infection that occurs within 30 days after randomization and involves the skin, subcutaneous tissue of the incision (superficial incisional), or the deep soft tissue (e.g., fascia, muscle) of the incision (deep incisional).
Pain of any severity15 and 45 days post randomizationPain intensity and related interference with usual daily activities, will be measured via the Brief Pain Inventory-Short Form (BPI-SF).The BPI-SF includes four 11-point numeric rating scales (NRS) of pain intensity, which measure average, least, and worst pain intensity in the past 24 hours (hrs.), respectively, as well as pain intensity now (0= no pain, 10= pain as bad as you can imagine).
Moderate to severe pain15 and 45 days post randomizationPain intensity and related interference with usual daily activities, will be measured via the Brief Pain Inventory-Short Form (BPI-SF).The BPI-SF includes four 11-point numeric rating scales (NRS) of pain intensity, which measure average, least, and worst pain intensity in the past 24 hours (hrs.), respectively, as well as pain intensity now (0= no pain, 10= pain as bad as you can imagine). Pain is of moderate or greater severity is defined by a score of ≥4/10 on a standard numeric rating scale (NRS) for pain.
Optimal pharmacological management for patients with atherosclerotic disease45 days post randomizationAmong patients with atherosclerotic disease, we will also assess optimal pharmacological management based upon whether patients are taking 0, 1, 2, or 3 of the following classes of efficacious medications at 45 days (i.e., an antiplatelet or anticoagulant drug; an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker; and a statin).
Optimal pharmacological management self-reported current smokers45 days post randomizationAmong patient who self-report to be current smokers at baseline, we will assess if patients are receiving pharmacological smoking cessation interventions at 45 days after randomization.
Days in hospital45 days post randomizationTotal number of days in hospital from randomization to 45 days post-randomization, including index hospital stay and any hospital readmission (s). A day in hospital is counted if a participant spends 1 minute of any day admitted to hospital.
Index length of hospital stay45 days post randomizationLength of hospital stay calculated from time of surgery completion (i.e., time of surgical wound closure) until discharge from the index hospitalization (measured in days and hours).

Other

MeasureTime frameDescription
Myocardial Infarction45 days post randomization4th Universal definition of myocardial infarction.
Acute Heart Failure45 days post randomizationThe definition of acute heart failure requires at least one of the following clinical signs (i.e., elevated jugular venous pressure, respiratory rales or crackles, crepitations, or presence of S3) with at least one of the following: 1. radiographic findings of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema, OR 2. heart failure treatment with a diuretic and documented clinical improvement.
Arrhythmia that results in patient presenting to an emergency department or being admitted to hospital45 days post randomizationAny arrhythmia that results in patient presenting to an emergency department, which includes an urgent care centre, or being admitted to hospital.
Death30 days post randomizationAll cause mortality.
Health-related quality of life (HRQL)45 days post randomizationHRQL will be measured with the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) instrument (https://euroqol.org/eq-5d-instruments/sample-demo) due to its increased sensitivity and validation in several countries including Canada. The EQ-5D-5L is also recommended in Canada to calculate the Quality Adjusted Life Years (QALYs) when conducting cost-effectiveness analyses. The EQ-5D-5L questionnaire consists of descriptive questions regarding 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), with a 5-level scale for participants to indicate the most accurate response (ranging from no problems to extreme problems).
Health services utilization-related costs45 days post randomizationCosts associated with hospital re-admission, length of stay, and healthcare utilization will be obtained from administrative datasets.
Infection45 days post randomizationInfection is defined as a pathologic process caused by the invasion of normally sterile tissue, fluid, or body cavity by pathogenic or potentially pathogenic organisms.
Re-operation45 days post randomizationRe-operation refers to any surgical procedure undertaken for any reason (e.g., wound dehiscence, infection).

Countries

Canada

Contacts

Primary ContactStephanie Harrison
stephanie.harrison@phri.ca905-594-0564
Backup ContactValerie Harvey
valerie.harvey@phri.ca905-594-0563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026